University Of Oxford — Sponsor Intelligence | 3 EU Trials

Filter these 3 trials by condition, phase, country and more.

3 Registered trials

1 Recruiting

2 Completed trials

11 Countries active

14 Unique IMPs

100% Results reported

Phase III

Phase III/IV

Phase IV

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

Top indications

3 total

RECOVERY Recruiting

2023-507441-29-00 Phase III 9 countries BALOXAVIR MARBOXIL; DEXAMETHASONE PH. EUR.; DEXAMETHASONE SODIUM PHOSPHATE; HYDR…
Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart… Ended

2022-502409-14-00 Phase III/IV 1 country
Cohort study of human mpox virus disease Ended

2022-501132-42-00 Phase IV 8 countries TECOVIRIMAT

Showing 1–3 of 3 trials